OBI Pharma holds EOP2 meeting with US FDA

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

OBI Pharma Awarded Level-A Recognition for TIPS Management

OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”

Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

Quick Takes on Promising New Approaches to Treating Breast Cancer